Affimed (AFMD) Competitors $0.57 -0.06 (-9.79%) Closing price 04/4/2025 03:59 PM EasternExtended Trading$0.59 +0.02 (+2.79%) As of 04/4/2025 07:18 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock AFMD vs. PEPG, ALVR, MRSN, VTVT, KPTI, IMRX, ONCY, CTMX, PDSB, and KRONShould you be buying Affimed stock or one of its competitors? The main competitors of Affimed include PepGen (PEPG), AlloVir (ALVR), Mersana Therapeutics (MRSN), vTv Therapeutics (VTVT), Karyopharm Therapeutics (KPTI), Immuneering (IMRX), Oncolytics Biotech (ONCY), CytomX Therapeutics (CTMX), PDS Biotechnology (PDSB), and Kronos Bio (KRON). These companies are all part of the "pharmaceutical products" industry. Affimed vs. PepGen AlloVir Mersana Therapeutics vTv Therapeutics Karyopharm Therapeutics Immuneering Oncolytics Biotech CytomX Therapeutics PDS Biotechnology Kronos Bio PepGen (NASDAQ:PEPG) and Affimed (NASDAQ:AFMD) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their media sentiment, community ranking, institutional ownership, dividends, earnings, risk, analyst recommendations, valuation and profitability. Is PEPG or AFMD more profitable? PepGen has a net margin of 0.00% compared to Affimed's net margin of -7,836.26%. PepGen's return on equity of -60.17% beat Affimed's return on equity.Company Net Margins Return on Equity Return on Assets PepGenN/A -60.17% -48.88% Affimed -7,836.26%-193.84%-107.24% Do insiders & institutionals have more ownership in PEPG or AFMD? 58.0% of PepGen shares are owned by institutional investors. Comparatively, 30.8% of Affimed shares are owned by institutional investors. 4.6% of PepGen shares are owned by insiders. Comparatively, 3.8% of Affimed shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Do analysts recommend PEPG or AFMD? PepGen currently has a consensus target price of $10.33, indicating a potential upside of 843.68%. Affimed has a consensus target price of $13.50, indicating a potential upside of 2,268.01%. Given Affimed's stronger consensus rating and higher probable upside, analysts plainly believe Affimed is more favorable than PepGen.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score PepGen 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33Affimed 0 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.80 Does the media prefer PEPG or AFMD? In the previous week, PepGen had 2 more articles in the media than Affimed. MarketBeat recorded 5 mentions for PepGen and 3 mentions for Affimed. Affimed's average media sentiment score of 0.66 beat PepGen's score of 0.12 indicating that Affimed is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment PepGen 0 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Affimed 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has preferable earnings & valuation, PEPG or AFMD? PepGen has higher earnings, but lower revenue than Affimed. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPepGenN/AN/A-$78.63M-$2.84-0.39Affimed$877K10.47-$114.66MN/AN/A Which has more risk and volatility, PEPG or AFMD? PepGen has a beta of 1.42, meaning that its stock price is 42% more volatile than the S&P 500. Comparatively, Affimed has a beta of 2.28, meaning that its stock price is 128% more volatile than the S&P 500. Does the MarketBeat Community favor PEPG or AFMD? Affimed received 419 more outperform votes than PepGen when rated by MarketBeat users. However, 80.00% of users gave PepGen an outperform vote while only 70.13% of users gave Affimed an outperform vote. CompanyUnderperformOutperformPepGenOutperform Votes2080.00% Underperform Votes520.00% AffimedOutperform Votes43970.13% Underperform Votes18729.87% SummaryPepGen beats Affimed on 8 of the 15 factors compared between the two stocks. Remove Ads Get Affimed News Delivered to You Automatically Sign up to receive the latest news and ratings for AFMD and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AFMD vs. The Competition Export to ExcelMetricAffimedPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$9.18M$6.35B$5.26B$7.12BDividend YieldN/A2.85%4.89%4.08%P/E RatioN/A6.8321.3817.51Price / Sales10.47187.43355.0688.78Price / CashN/A65.6738.1834.64Price / Book0.145.576.233.79Net Income-$114.66M$141.89M$3.21B$247.48M7 Day Performance-27.01%-11.51%-8.47%-6.79%1 Month Performance-44.65%-16.59%-4.87%-11.53%1 Year Performance-91.20%-18.14%2.54%-7.82% Affimed Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AFMDAffimed4.1947 of 5 stars$0.57-9.8%$13.50+2,268.0%-91.3%$9.18M$877,000.000.00200Analyst ForecastShort Interest ↓News CoverageGap UpPEPGPepGen1.9644 of 5 stars$1.70-4.0%$10.33+507.8%-90.6%$55.58MN/A-0.5730Gap DownALVRAlloVirN/A$11.00-3.5%N/A-57.7%$55.47MN/A-0.54110High Trading VolumeMRSNMersana Therapeutics4.2751 of 5 stars$0.44+4.6%$4.00+799.3%-92.9%$55.44M$40.50M-0.73150Short Interest ↓VTVTvTv Therapeutics1.1706 of 5 stars$17.37+4.4%$35.00+101.5%-36.2%$55.41M$1.02M-3.839Gap DownKPTIKaryopharm Therapeutics3.2306 of 5 stars$6.51+1.4%$57.50+783.3%-80.7%$54.80M$145.24M-6.38380Gap DownIMRXImmuneering3.2284 of 5 stars$1.74-3.3%$11.00+532.2%-40.0%$54.03M$320,000.00-0.8860Short Interest ↓Gap DownONCYOncolytics Biotech1.0686 of 5 stars$0.63-0.1%$4.00+535.6%-56.9%$53.81MN/A-2.3330CTMXCytomX Therapeutics3.9984 of 5 stars$0.67+0.5%$5.02+649.6%-77.9%$53.67M$138.10M3.94170PDSBPDS Biotechnology1.5261 of 5 stars$1.37flat$11.67+751.6%-71.1%$52.32MN/A-1.1820Short Interest ↓Gap DownKRONKronos Bio3.6654 of 5 stars$0.87-0.4%$1.63+87.5%-35.1%$52.30M$9.85M-0.61100Short Interest ↓Positive NewsGap Down Remove Ads Related Companies and Tools Related Companies PEPG Competitors ALVR Competitors MRSN Competitors VTVT Competitors KPTI Competitors IMRX Competitors ONCY Competitors CTMX Competitors PDSB Competitors KRON Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:AFMD) was last updated on 4/5/2025 by MarketBeat.com Staff From Our PartnersFeds Just Admitted It—They Can Take Your CashThe Government Just Said Your Money Isn't Yours That's right—According to the DOJ, YOUR hard-earned money i...Priority Gold | Sponsored[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredAmerica’s Retirement Accounts Are at Risk—Here’s WhyWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredTrump’s Secret WeaponPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsMusk confirmed that SpaceX's Starship will carry Optimus to Mars in 2026 as part of an autonomous mission to h...InvestorPlace | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredAll Signs Point To Collapse - 401(k)s/IRAs /Are DoomedRetiring? Not so Fast..Hold Onto Your Bootstraps For A Long Road AheadAmerican Hartford Gold | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Affimed Please log in to your account or sign up in order to add this asset to your watchlist. Share Affimed With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy AFMD Stock Free AFMD Stock Alerts